Finance

Lists
KLBF:IDX
Kalbe Farma Tbk PT
780,00 IDR
0,00%
(0,00) 1D
15-окт., 09:23:53 GMT+7  ·   IDR
All symbols
SymbolPriceChange% Change
Generating top insights for KLBF...
Open
780 IDR
High
785 IDR
Low
775 IDR
Mkt. cap
36,51 трлн
Avg. vol.
63,64 млн
Volume
2,69 млн
Dividend
2,56%
Quarterly dividend
5 IDR
Ex-dividend date
2026-ж., 4-июн.
P/E ratio
9,80
52-wk high
1 345 IDR
52-wk low
630 IDR
EPS
80 IDR
Shares outstanding
46,81 млд
No. of employees
13 миң
Open
780 IDR
High
785 IDR
Low
775 IDR
Mkt. cap
36,51 трлн
Avg. vol.
63,64 млн
Volume
2,69 млн
Dividend
2,56%
Quarterly dividend
5 IDR
Ex-dividend date
2026-ж., 4-июн.
P/E ratio
9,80
52-wk high
1 345 IDR
52-wk low
630 IDR
EPS
80 IDR
Shares outstanding
46,81 млд
No. of employees
13 миң
News stories
From web sources and news partners
Profile
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
About Kalbe Farma Tbk PT
CEO-
Employees12,8 миң
Founded1966-ж., 10-сен.
Headquarters-
SectorPharmaceutical industry
Websitekalbe.co.id
Last report
2026-ж., 28-июл.
Fiscal period
Q2 2026
19,68 IDR / 20,14 IDR
-2,28%miss
Revenue / Est. (IDR)
9,80 трлн / -
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in IDR
Loading Previous Earnings...
Revenue
Net income
All values in IDR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
8,91 трлн
9,34 трлн
9,68 трлн
9,80 трлн
Cost of goods sold
5,46 трлн
5,92 трлн
6,02 трлн
6,25 трлн
Cost of revenue
5,46 трлн
5,92 трлн
6,02 трлн
6,25 трлн
Research and development expenses
98,31 млд
160,88 млд
113,14 млд
122,60 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,51 трлн
1,95 трлн
2,23 трлн
2,27 трлн
Operating expense
2,60 трлн
2,14 трлн
2,33 трлн
2,39 трлн
Total operating expenses
8,06 трлн
8,05 трлн
8,36 трлн
8,64 трлн
Operating income
851,77 млд
1,28 трлн
1,32 трлн
1,16 трлн
Other non operating income
-3,78 млд
-4,17 млд
-3,63 млд
-3,74 млд
EBT including unusual items
877,87 млд
1,30 трлн
1,36 трлн
1,19 трлн
EBT excluding unusual items
888,55 млд
1,30 трлн
1,36 трлн
1,18 трлн
Income tax expense
211,19 млд
252,81 млд
303,84 млд
271,57 млд
Effective tax rate
24,06%
19,41%
22,40%
22,80%
Other operating expenses
-7,23 млд
31,35 млд
-10,02 млд
2,13 млд
Net income
656,41 млд
1,03 трлн
1,03 трлн
890,54 млд
Net profit margin
7,37%
11,07%
10,63%
9,09%
Earnings per share
14,44
22,72
22,74
19,68
Interest and investment income
41,31 млд
40,43 млд
32,07 млд
43,61 млд
Interest expense
-9,69 млд
-5,77 млд
-4,61 млд
-6,78 млд
Net interest expenses
31,62 млд
34,66 млд
27,46 млд
36,83 млд
Depreciation and amortization charges
-
-
-
-
EBITDA
1,05 трлн
1,45 трлн
1,51 трлн
1,20 трлн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору